Navigation Links
Avanir Pharmaceuticals Reports Fiscal 2012 Third Quarter Financial And Business Results
Date:8/8/2012

ALISO VIEJO, Calif., Aug. 8, 2012 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today reported financial results for the three and nine months ended June 30, 2012.

Quarterly Financial Highlights

  • Gross and net NUEDEXTA® sales of $12.2 million and $10.1 million, respectively
  • Total company net revenues of $10.5 million
  • Cash, cash equivalents, and restricted investments of $84.1 million as of June 30, 2012
  • "Our fiscal third quarter results reflect another significant increase in net sales of NUEDEXTA seen in both our retail and institutional business," said Keith A. Katkin, president and CEO of Avanir. "Going forward, our commercial team will continue to drive revenue growth by increasing recognition of pseudobulbar affect and awareness of NUEDEXTA as the only FDA-approved treatment."

    Fiscal 2012 Third Quarter Results

  • Total net revenues for the quarter ended June 30, 2012 were $10.5 million, compared with $2.5 million for the comparable quarter in 2011. Total net revenues consist of NUEDEXTA revenue and royalty revenue from Abreva®.
  • Total operating expenses were $24.7 million in the third quarter of fiscal 2012, compared with $18.4 million in the comparable period in fiscal 2011.
  • Cash used in operations was $14.9 million in the third quarter of fiscal 2012.
  • Net loss for the fiscal 2012 third quarter was $15.0 million, or $0.11 per share, compared with a net loss of $16.1 million, or $0.13 per share, for the same period in fiscal 2011.
  • Nine-Month Results

  • Total net revenues for the first nine-months of fiscal 2012 totaled $27.7 million, compared with $5.7 million for the first nine-months of fiscal 2011.
  • Total operating expenses were $74.1 million in the first nine-months of fiscal 2012, compared to $48.1 million in the comparable period for fi
    '/>"/>

  • SOURCE Avanir Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Avanir Pharmaceuticals to Participate in Citi 2012 Global Health Care Conference
    2. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
    3. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
    4. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
    5. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
    6. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
    7. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
    8. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
    9. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
    10. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
    11. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/27/2015)... The Medical Innovation Impact Index (MI3), ... on medical innovation, has been developed at the ... Dickinson University’s ( FDU ) Rothman Institute of Innovation ... to new FDA (Food & Drug Administration) draft guidance ... of certain medical devices. , “The main impediment ...
    (Date:5/26/2015)... (PRWEB) May 26, 2015 Regenestem ... new stem cells clinic in Buenos Aires, Argentina. The ... renowned critical care specialist. Pastrana has assembled a multidisciplinary ... and orthopedics in her state-of-the-art Puerto Madero office. ... phase I to phase IV clinical studies in cellular ...
    (Date:5/26/2015)... REDWOOD CITY , Kalifornien und HILDEN, ... QIAGEN Clinical Insight ... Interpretation von Genvarianten und die Erstellung dazugehöriger ... und ESHG     QIAGEN N.V. ... QIA) gab heute die Markteinführung von QIAGEN ...
    (Date:5/26/2015)... , May 26, 2015   Intrexon Corporation (NYSE: ... that Gregory Frost , Ph.D., Senior Vice President and ... 2015 Global Healthcare Conference on Wednesday, June 3 rd , ... New York City . About ... is Powering the Bioindustrial Revolution with Better DNA ™ ...
    Breaking Biology Technology:Medical Innovation Impact Index Launched at Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) under the Rothman Institute 2Regenestem Network and Silvina Pastrana, M.D. Announce the Opening of a New Stem Cell Clinic in Buenos Aires 2Regenestem Network and Silvina Pastrana, M.D. Announce the Opening of a New Stem Cell Clinic in Buenos Aires 3QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 2QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 3QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 4QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 5QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 6Intrexon to Present at the Jefferies 2015 Global Healthcare Conference 2
    ... ReportsnReports announces it will carry , , Daptomycin ... Browse the complete , , Daptomycin - Comprehensive patent,search ... Market Research,Reports Browse All ... Eliminate unnecessary risk with the industry benchmark in,comprehensive patent information. ...
    ... nation,s long-term clean-energy future, but the technology has come ... Fukushima disaster. Indeed, many nations have called for checks ... safely. In the United States, about 20 ... the electricity from emission-free sources, including renewable technologies and ...
    ... Cebix Incorporated announced today that preclinical data for ... demonstrated a half-life of three days as compared to ... in nerve conduction velocity, a measure of the rate ... an animal model of diabetic peripheral neuropathy. Additionally, clinical ...
    Cached Biology Technology:ReportsnReports - Daptomycin - Comprehensive Patent Search 2ReportsnReports - Daptomycin - Comprehensive Patent Search 3ReportsnReports - Daptomycin - Comprehensive Patent Search 4ReportsnReports - Daptomycin - Comprehensive Patent Search 5Berkeley scientists pioneer nanoscale nuclear materials testing capability 2Cebix's Long-Acting C-Peptide Ersatta™ has Potential in Multiple Chronic Complications of Diabetes 2Cebix's Long-Acting C-Peptide Ersatta™ has Potential in Multiple Chronic Complications of Diabetes 3
    (Date:5/21/2015)... 21, 2015 The Sync Project™ , ... for health, today announced a collaborative partnership with ... will center on collaboration on original research, joint course ... in the collaboration, The Sync Project and BerkleeICE are ... Medicine" in the 2015-2016 academic year.  ...
    (Date:5/19/2015)... Research and Markets ( ... the  "Genetic Testing Market Outlook 2018"  report ... ,A recent report, Genetic Testing Market Outlook ... current and future genetic testing market. A ... principles and types are covered in this ...
    (Date:5/11/2015)... DAYTON, Ohio , May 11, 2015  Through a ... Ohio had a strong showing at AUVSI,s ... . These representatives of Ohio,s UAS ... domestic and abroad from all points along the UAS ecosystem. ... Dayton Development Coalition,s (DDC) Vice President for Aerospace Rich ...
    Breaking Biology News(10 mins):The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3Global Genetic Testing Market Outlook 2018 2Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2
    ... and ecological sustainability of biofuels and the impact of ... America will take place on Friday, Dec. 5, in ... Neotropical Forests: Trends, Implications and Emerging Alternatives, is sponsored ... the Program in Native Species Reforestation, both joint programs ...
    ... Associated Professor, DSc Barbara Ann Halkier, Department of ... Life Sciences, University of Copenhagen, has been granted ... award for her excellent research into secondary metabolites, ... plants. In particular, her research has focused ...
    ... Company Experiences Record Revenue Growth from Operations in Third Quarter , ... bioMETRX, Inc. (OTC Bulletin Board: BMRX), a leading developer of consumer-based ... ending September 30, 2008. , , ... 430% increase over second quarter revenues of $100,000. , ...
    Cached Biology News:Conference to explore sustainability of biofuels 2The Danisco Award 2008 goes to D.Sc. Barbara Ann Halkier from Faculty of Life Sciences, Copenhagen 2bioMETRX, Inc. Highlights 3rd Quarter 2008 Financial Results 2
    Mouse monoclonal antibody raised against a partial recombinant AAAS. NCBI Entrez Gene ID = AAAS...
    Rabbit polyclonal to MCP2 ( Abpromise for all tested applications). entrezGeneID: 6355 SwissProtID: P49873...
    ... A sensitive and high speed homogeneous ... phosphatase activity and for screening of inhibitors ... kit is based on a fluorescence superquenching ... radioactive label. The universal platform provides flexibility ...
    ... PowerPac 3000 power supply, 220-240 V, is ... liquid-phase isoelectric focusing (IEF). The system includes ... (60 ml) focusing chambers, chassis, harvesting apparatus, ... supply, 10 ml Bio-Lyte ampholytes (pH 3-10), ...
    Biology Products: